Evidence map›Paper›PMID 42761508›Full record

ArticleBlood neoplasia2026

Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors.

Wei Tan, Jianliang Dai, Chutima Kunacheewa, Melody R Becnel, Hans C Lee, Krina K Patel, David A Berrios Nolasco, Mei Huang, Amishi U Vora, Sheeba K Thomas and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wei TanDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jianliang DaiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chutima KunacheewaDivision of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Melody R BecnelDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hans C LeeDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Krina K PatelDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
David A Berrios NolascoDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mei HuangDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Amishi U VoraDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sheeba K ThomasDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Oren PasvolskyDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Zuzana Lutter-BerkaDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Isere KuiatseDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Neha S KordeDepartment of Multiple Myeloma, Memorial Sloan Kettering Cancer Center, New York City, NY.
Sundar JagannathDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Ola LandgrenSylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Suyu LiuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elisabet E ManasanchDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Robert Z OrlowskiDepartment of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42761508
PMCPMC13586678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.